Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Neumirna Therapeutics Aps is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters involve 2 distinct examiners, with each examiner reviewing a separate active application. The prosecution is also spread across 2 distinct art units, indicating that the company's biotechnological filings are categorized into different technical niches. This distribution suggests that the company is pursuing multiple distinct lines of inquiry within the pharmaceutical sector.
The busiest examiner for the portfolio is GIBBS, TERRA C, who is responsible for 1 pending office action. Since the busiest examiner pending count is 1, the workload is shared equally between the examiners. Practitioners must manage the expectations of GIBBS, TERRA C and the other examiner while navigating the specific rules of the assigned art units. This structure means that the outcome of the 2 pending office actions will depend on the independent assessments of 2 distinct examiners in 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GIBBS, TERRA C | 1 | 63.7% | +10.3% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.0% | +18.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18552318 | MICRORNA-27B INHIBITORS | GIBBS, TERRA C | 3d overdue |
| 18552335 | MICRORNA-134 INHIBITORS | POLIAKOVA-GEORGAN, EKATERINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18552318 | MICRORNA-27B INHIBITORS | GIBBS, TERRA C | 3d overdue |
| 18552335 | MICRORNA-134 INHIBITORS | POLIAKOVA-GEORGAN, EKATERINA | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18552318 | MICRORNA-27B INHIBITORS | GIBBS, TERRA C | 1635 | §103§112 | Final Rejection | 3d overdue | Pending | Sep 25, 2023 |
| 18552335 | MICRORNA-134 INHIBITORS | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103§112 | Non-Final OA | — | Pending | Sep 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial